Proteon Pharmaceuticals
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
% growth | - | 110 % | 50 % | 72 % | (14 %) | 6 % | - |
EBITDA | (1.1m) | (2.1m) | (3.4m) | (3.1m) | (4.0m) | - | - |
% EBITDA margin | (863 %) | (779 %) | (853 %) | (448 %) | (673 %) | - | - |
Profit | (1.6m) | (2.5m) | (4.2m) | (3.6m) | (4.4m) | - | - |
% profit margin | (1249 %) | (930 %) | (1041 %) | (513 %) | (739 %) | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Early VC | ||
N/A | €9.5m | Series A | |
€21.0m | Series B | ||
Total Funding | €30.5m |
Recent News about Proteon Pharmaceuticals
EditProteon Pharmaceuticals leverages precision biology to develop microbiome protection solutions aimed at improving animal and human health. Operating in the animal health sector, the company partners with farmers to enhance the economic efficiency of farms through environmentally sustainable and natural solutions. Proteon's core products include feed additives that prevent and eliminate infections in poultry and aquaculture, thereby reducing the need for antibiotics. The company employs advanced technologies such as bioinformatics, Artificial Intelligence, genomic sequencing, materials engineering, and molecular biology in its proprietary Phage Development Platform. This platform has been refined over more than a decade of research and development in bacteriophages, which are viruses that target and destroy specific bacteria. By focusing on precision-targeted solutions, Proteon aims to address the overuse of antibiotics in livestock farming, which is a significant concern for both animal and human health. The business model involves partnering with farmers and distributors to deliver these innovative solutions, generating revenue through product sales and strategic partnerships.
Keywords: precision biology, microbiome protection, animal health, human health, antibiotic reduction, feed additives, bacteriophages, bioinformatics, AI, genomic sequencing.